Skip to main content
Aller à la page d’accueil de la Commission européenne (s’ouvre dans une nouvelle fenêtre)
français fr
CORDIS - Résultats de la recherche de l’UE
CORDIS

Bioinspired Modulation of Cardiac Troponin I Splicing to Treat Diastolic Dysfunction

Objectif

Diastolic dysfunction, i.e. impaired cardiac relaxation and filling, is a hallmark shared by various heart diseases, including hypertrophic cardiomyopathy (HCM) and heart failure with preserved ejection fraction (HFpEF). It is often driven by excessive calcium sensitivity of the cardiac myofilaments, and in HCM and HFpEF alike, is associated with disrupted adrenergic signalling, culminating in reduced responsiveness of the heart to adrenaline. In the healthy heart, adrenergic stimulation normally decreases myofilament calcium sensitivity via phosphorylation of the N-terminus of cardiac troponin I (cTnI). Remarkably, this effect can also be mimicked by truncation of the cTnI N-terminus. We recently discovered that small mammals such as bats and shrews, which have extraordinarily high cardiac demands, have evolved to skip the exon encoding the cTnI N-terminus via alternative splicing or genomic deletion. This creates a permanently desensitized cTnI, bypassing the need for sustained β-adrenergic signalling. While alternative splicing of cTnI does not naturally occur in humans or most other mammals, it could be therapeutically induced using antisense oligonucleotides (AONs) in order to increase myocardial relaxation rate. TROPOSplice aims to develop a splice-switching antisense therapeutic that induces cTnI exon 3 skipping to mimic the myofilament desensitizing effect of adrenaline, leveraging a bioinspired strategy “from bats to bedside”. Crucially, as this approach acts downstream of adrenergic receptors, it is compatible with mainstay cardiovascular treatments such as beta-blockers. We will adopt a translational approach, from cultured cardiomyocytes to in vivo mouse models, to optimise AON design and delivery and to investigate the physiological effects of induced cTnI exon 3 skipping. This project offers a novel, evolution-guided therapeutic strategy to treat diastolic dysfunction and could ultimately benefit patients with HCM, HFpEF, and related heart conditions.

Champ scientifique (EuroSciVoc)

Ce projet n'a pas encore été classé par EuroSciVoc.
Proposez les domaines scientifiques qui vous semblent les plus pertinents et aidez-nous à améliorer notre service de classification.

Mots‑clés

Programme(s)

Thème(s)

Régime de financement

HORIZON-ERC - HORIZON ERC Grants

Voir tous les projets financés dans le cadre de ce programme de financement

Appel à propositions

(s’ouvre dans une nouvelle fenêtre) ERC-2026-STG

Voir tous les projets financés au titre de cet appel

Institution d’accueil

CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CARLOS III (F.S.P.)
Contribution nette de l'UE
€ 1 499 625,00
Adresse
CALLE MELCHOR FERNANDEZ ALMAGRO 3
28029 Madrid
Espagne
Région
Comunidad de Madrid Comunidad de Madrid Madrid
Type d’activité
Research Organisations
Liens
Coût total
€ 1 499 625,00

Bénéficiaires (1)